Latest International Vaccine Institute Stories
SEOUL, Republic Of Korea, Sept.
-- Campaign consists of video and microsite to promote awareness of IVI and grassroots fundraising to support R&D of vaccine for developing countries SEOUL, South Korea, July 2, 2014
A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years.
Scientists from the International Vaccine Institute (IVI) have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 ("swine flu") virus.
Innovation in the design of vaccines is rapidly expanding their use, safety, and effectiveness for disease prevention and therapeutic interventions.